Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112808 | 1.00 | CYP1A2 (0.49) | CYP1A2NPC1SMN1; SMN2RAB9AKMT2A | |
| SCHEMBL29496852 | 0.81 | NPC1 (0.71) | CYP1A2NPC1SMN1; SMN2RAB9AKMT2A | |
| SCHEMBL22925017 | 0.80 | LMNA (0.66) | CYP1A2NPC1SMN1; SMN2RAB9AKMT2A | |
| SCHEMBL7747081 | 0.76 | MAOB (0.50) | NPC1SMN1; SMN2RAB9AKMT2AMAOB | |
| SCHEMBL7747082 | 0.76 | MAOB (0.50) | NPC1SMN1; SMN2RAB9AKMT2AMAOB | |
| SCHEMBL23081589 | 0.75 | MIF (0.62) | CYP1A2NPC1SMN1; SMN2RAB9AKMT2A | |
| SCHEMBL13903485 | 0.75 | MIF (0.62) | CYP1A2NPC1SMN1; SMN2RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL5702977 | 0.74 | MAOB (0.49) | NPC1SMN1; SMN2RAB9AKMT2AMAOB | |
| Hydrochloric Acid SCHEMBL5702982 | 0.74 | MAOB (0.49) | NPC1SMN1; SMN2RAB9AKMT2AMAOB | |
| SCHEMBL22925057 | 0.74 | NPC1 (0.78) | CYP1A2NPC1SMN1; SMN2RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| WO-2021046515-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | CANO IVAN COLLADO (ES) | 2004-05-27 | — | — | US | disclosed |
| EP-1335908-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002038553-A2 | TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | PPARG, PPARA, PPARD | CYP1A2 430/4885NPC1 739/4885SMN1; SMN2 4345/4885 |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | CYP1A2 4782/4885NPC1 1506/4885SMN1; SMN2 998/4885 |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | CYP1A2 4782/4885NPC1 1506/4885SMN1; SMN2 998/4885 |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | PPARG, PPARA, PPARD | CYP1A2 452/4885NPC1 604/4885SMN1; SMN2 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.